Clinical Trial Update: Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction [Phase 3]

View source ↗

Summary

Phase 3 trial investigating sacubitril/valsartan for myocardial oxygenation and fibrosis in heart failure with preserved ejection fraction was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Sacubitril/Valsartan (sacubitril/valsartan)

Snippet

Sponsor: Flinders University | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 3 | Status: WITHDRAWN